calcipotriene and betamethasone dipropionate

FDA Drug Profile — ENSTILAR, TACLONEX, Attero, calcipotriene and betamethasone dipropionate

calcipotriene and betamethasone dipropionate is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand names including ENSTILAR, TACLONEX, Attero. Available dosage forms: aerosol, foam, suspension, solution.

Drug details

Generic Name
calcipotriene and betamethasone dipropionate
Brand Names
ENSTILAR, TACLONEX, Attero, calcipotriene and betamethasone dipropionate
Application Number
NDA207589
Sponsor
LEO Pharma Inc.
NDC Codes
4
Dosage Forms
AEROSOL, FOAM, SUSPENSION, SOLUTION
Routes
TOPICAL
Active Ingredients
CALCIPOTRIENE MONOHYDRATE, BETAMETHASONE DIPROPIONATE, CALCIPOTRIENE HYDRATE, CALCIPOTRIENE

Indications and Usage

1 INDICATIONS AND USAGE ATTERO™ Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp in patients 12 years and older and plaque psoriasis of the scalp and body in patients 18 years and older. Additional pediatric use information is approved for LEO Pharma A/S's Taclonex ® (calcipotriene and betamethasone dipropionate) Topical Suspension. However, due to LEO Pharma A/S's marketing exclusivity rights, this drug product is not labeled with that information. ATTERO™ Topical Suspension is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis of the scalp in patients 12 years and older and plaque psoriasis of the scalp and body in patients age 18 years and older. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.